港股异动 | 创新药概念股上涨，劲方医药涨超9%！国办发文健全药价形成机制，花旗研报称创新药企有望受益

智通财经04-15

4月15日，创新药概念股上涨，劲方医药-B涨超9%，信达生物涨超4%，恒瑞医药、石药集团跟涨。消息面上，4月14日，国务院办公厅印发《关于健全药品价格形成机制的若干意见》，提出14条举措，包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、引导药店合理制定药品零售价格、强化短缺药保供稳价等。花旗发布研报称，这是自2015年以来中央政府在药品定价方面出台的最重要的指导性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2627479216?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2026-04-15 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627479216","market":"hk","top_or_hot":-1,"title":"港股异动 | 创新药概念股上涨，劲方医药涨超9%！国办发文健全药价形成机制，花旗研报称创新药企有望受益","media":"智通财经","content":"<div>\n<p>4月15日，创新药概念股上涨，劲方医药-B涨超9%，信达生物涨超4%，恒瑞医药、石药集团跟涨。消息面上，4月14日，国务院办公厅印发《关于健全药品价格形成机制的若干意见》，提出14条举措，包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、引导药店合理制定药品零售价格、强化短缺药保供稳价等。花旗发布研报称，这是自2015年以来中央政府在药品定价方面出台的最重要的指导性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1428631.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 创新药概念股上涨，劲方医药涨超9%！国办发文健全药价形成机制，花旗研报称创新药企有望受益</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 创新药概念股上涨，劲方医药涨超9%！国办发文健全药价形成机制，花旗研报称创新药企有望受益\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-15 10:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1428631.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月15日，创新药概念股上涨，劲方医药-B涨超9%，信达生物涨超4%，恒瑞医药、石药集团跟涨。消息面上，4月14日，国务院办公厅印发《关于健全药品价格形成机制的若干意见》，提出14条举措，包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、引导药店合理制定药品零售价格、强化短缺药保供稳价等。花旗发布研报称，这是自2015年以来中央政府在药品定价方面出台的最重要的指导性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1428631.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YR35.GBP","symbol_name":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1428631.html","article_id":"2627479216","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627479216","pubTimestamp":1776219660,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"4月15日，创新药概念股上涨，$劲方医药-B$涨超9%，$信达生物$涨超4%，$恒瑞医药$、$石药集团$跟涨。重点创新药企/生物制药公司将成为受益者，如$恒瑞医药$、石药集团、信达生物以及其他跨国公司。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","02595":"劲方医药-B","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","BK1574":"生物医药B类股","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU0359201612.USD":"贝莱德中国基金A2","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK4504":"桥水持仓","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK4588":"碎股","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1521":"挪威政府全球养老基金持仓","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","BK4566":"资本集团","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC"},"translate_title":"Changes in Hong Kong stocks | Innovative drug concept stocks rose, Jinfang Pharmaceutical rose by more than 9%! The State Office issued a document to improve the drug price formation mechanism, and Citi indicated that innovative pharmaceutical companies such as Hengrui are expected to benefit","themeId":"91f24949debf4aed7e22faec526c7ddd","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/c254a50737dd40bd5d55b71b5605f4b0","symbols_score_info":{"02595":2},"content_text":"4月15日，创新药概念股上涨，劲方医药-B涨超9%，信达生物涨超4%，恒瑞医药、石药集团跟涨。消息面上，4月14日，国务院办公厅印发《关于健全药品价格形成机制的若干意见》，提出14条举措，包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、引导药店合理制定药品零售价格、强化短缺药保供稳价等。花旗发布研报称，这是自2015年以来中央政府在药品定价方面出台的最重要的指导性文件，将其视为政府明确承诺扶持具有全球竞争力的本土制药和生物医药产业的重要信号。政策目标是让市场在药品价格形成中发挥更大决定性作用。重点创新药企/生物制药公司将成为受益者，如恒瑞医药、石药集团、信达生物以及其他跨国公司。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627479216","isCrawlerRequest":true}